Psychiatr. praxi. 2024;25(2):62-70 | DOI: 10.36290/psy.2024.011

Toxic psychosis and its clinical significance

Mgr. Ing. Irena Semančíková1, 2, MUDr. Miloslav Kopeček, Ph.D.3, 4, prof. Mgr. Ondřej Bezdíček, Ph.D.1
1 Neurologická klinika a Centrum klinických neurověd, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze
2 Psychiatrická nemocnice Bohnice, Praha
3 Národní ústav duševního zdraví, Klecany
4 Klinika psychiatrie a lékařské psychologie, 3. lékařská fakulta Univerzity Karlovy, Praha

The review article focuses on the diagnostics, clinical symptoms and therapy of "toxic psychoses", i.e., substance-induced psychotic disorders, the prevalence of which increased significantly in recent decades due to a considerable increase in the production and consumption of psychoactive substances. This is a type of mental and behavioral disorders caused by the use of psychoactive substances, resulting in secondary psychosis. Differential diagnostics focuses mainly on distinguishing the symptoms of toxic psychosis from schizophrenia, where especially positive symptomatology can overlap. Due to the heterogeneity of the group of toxic psychoses, the article further focuses on distinguishing individual forms according to the inducing psychoactive substance, including their therapy.

Keywords: psychosis, substance, diagnostics, methamphetamine, cannabis.

Accepted: May 29, 2024; Published: June 3, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Semančíková I, Kopeček M, Bezdíček O. Toxic psychosis and its clinical significance. Psychiatr. praxi. 2024;25(2):62-70. doi: 10.36290/psy.2024.011.
Download citation

References

  1. Hosák L, Hrdlička M, Libiger J. Psychiatrie a pedopsychiatrie. Nakladatelství Karolinum, 2019.
  2. Popov P. Toxické psychózy. In: Horáček a kol.: Psychotické stavy v klinické praxi. Amepra s.r.o., 2003
  3. Semančíková I, Bezdíček O. Vývoj výskytu toxických psychóz v souvislosti s užíváním psychoaktivních látek v České republice. Čes a slov Psychiat. 2023; 119(3): 102-108.
  4. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth edition. Arlington, VA, American Psychiatric Association, 2013. Go to original source...
  5. https://icd.who.int/ct11/icd11_mms/en/release, česká verze: https://www.uzis.cz/ext/mkn-11-nahled/#ct
  6. Smolík P. Duševní a behaviorální poruchy, průvodce klasifikací, nástin nozologie, diagnostika. Maxdorf. 1996.
  7. Mohr P, Libiger J, Pavlovský P. Diagnostická kritéria DSM-5-TR. Praktická příručka s kódy MKN-10 a MKN-11.Hogrefe - Test centrum s.r.o., Praha, 2023
  8. 8. 10. revize Mezinárodní klasifikace nemocí, česká verze, platnost od 1. 1. 2023. https://mkn10.uzis.cz/prohlizec/F10-F19
  9. Perälä J, Kuoppasalmi K, Pirkola S, et al. Alcohol-induced psychotic disorder and delirium in the general population. Br J Psychiatry. 2010 Sep;197(3):200-6. Go to original source... Go to PubMed...
  10. Jordaan GP, Nel DG, Hewlett RH, et al. Alcohol-induced psychotic disorder: a comparative study on the clinical characteristics of patients with alcohol dependence and schizophrenia. J Stud Alcohol Drugs. 2009 Nov;70(6):870-6. Go to original source... Go to PubMed...
  11. Soyka M. Psychopathological characteristics in alcohol hallucinosis and paranoid schizophrenia. Acta Psychiatr Scand. 1990 Mar;81(3):255-9. Go to original source... Go to PubMed...
  12. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009 Oct;259(7):413-31. Go to original source... Go to PubMed...
  13. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-28. Go to original source... Go to PubMed...
  14. Schoeler T, Ferris J, Winstock AR. Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis. Transl Psychiatry. 2022 Sep 6;12(1):369. Go to original source... Go to PubMed...
  15. Padhi D, Shukla P, Chaudhury S. Sociodemographic and clinical profile of cannabis-induced psychosis: A comparative study. Ind Psychiatry J. 2021 Oct;30(Suppl 1):S132-S139. Go to original source... Go to PubMed...
  16. Núñez LA, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand. 2002 Mar;105(3):173-8. Go to original source... Go to PubMed...
  17. Vergara-Moragues E, Mestre-Pintó JI, Gómez PA, et al. Can symptoms help in differential diagnosis between substance-induced vs independent psychosis in adults with a lifetime diagnosis of cocaine use disorder? Psychiatry Res. 2016 Aug 30;242:94-100. Go to original source... Go to PubMed...
  18. Smith-Kielland A, Skuterud B, Morland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol. 1999;23:323-332. Go to original source... Go to PubMed...
  19. Vergara-Moragues E, González-Saiz F, Lozano OM, et al. Psychiatric comorbidity in cocaine users treated in therapeutic community: substance-induced versus independent disorders. Psychiatry Res. 2012 Dec 30;200(2-3):734-41. Go to original source... Go to PubMed...
  20. Roncero C, Comín M, Daigre C, et al. Clinical differences between cocaine-induced psychotic disorder and psychotic symptoms in cocaine-dependent patients. Psychiatry Res. 2014 May 30;216(3):398-403. Go to original source... Go to PubMed...
  21. Fiorentini A, Cantù F, Crisanti C, et al. Substance-Induced Psychoses: An Updated Literature Review. Front Psychiatry. 2021 Dec 23;12:694863. Go to original source... Go to PubMed...
  22. Arunogiri S, Verdejo-Garcia A, McKetin R, et al. Emotion Recognition and Impulsive Choice in Relation to Methamphetamine Use and Psychosis Symptoms. Front Psychiatry. 2019 Dec 13;10:889. Go to original source... Go to PubMed...
  23. Hides L, Dawe S, McKetin R, et al. Primary and substance-induced psychotic disorders in methamphetamine users. Psychiatry Res. 2015 Mar 30;226(1):91-6. Go to original source... Go to PubMed...
  24. Gan H, Zhao Y, Jiang H, et al. A Research of Methamphetamine Induced Psychosis in 1,430 Individuals With Methamphetamine Use Disorder: Clinical Features and Possible Risk Factors. Front Psychiatry. 2018 Nov 6;9:551. Go to original source... Go to PubMed...
  25. Harris D, Batki SL. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict. 2000 Winter;9(1):28-37. Go to original source... Go to PubMed...
  26. Srisurapanont M, Ali R, Marsden J, et al. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003 Dec;6(4):347-52. Go to original source... Go to PubMed...
  27. McKetin R, Baker AL, Dawe S, et al. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. Psychiatry Res. 2017 May;251:349-354. Go to original source... Go to PubMed...
  28. Voce A, Calabria B, Burns R, et al. A Systematic Review of the Symptom Profile and Course of Methamphetamine-Associated Psychosis. Subst Use Misuse. 2019;54(4):549-559. Go to original source... Go to PubMed...
  29. Sara G, Burgess P, Malhi GS, et al. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophr Res. 2013;147(2-3):216-22. Go to original source... Go to PubMed...
  30. Yui K, Goto K, Ikemoto S, et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry. 1999 Nov;4(6):512-23. Go to original source... Go to PubMed...
  31. Wearne TA, Cornish JL. A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology. Front Psychiatry. 2018 Oct 10;9:491. Go to original source... Go to PubMed...
  32. Kopeček M, Andrashko V. Racemický ketamin v léčbě rezistentní depresivní poruchy. Od výzkumu ke klinické off-label aplikaci. Psychiatrie. 2022; 26(4): 146-155.
  33. Kopeček M, Andrashko V. Pokračovací a udržovací léčba rezistentní depresivní poruchy racemickým ketaminem. Přehled studií. Psychiatrie. 2023; 27(4): 168-178.
  34. Pereiro C, Pino C, Flórez G, Arrojo M, Becoña E; COPSIAD Group. Psychiatric Comorbidity in Patients from the Addictive Disorders Assistance Units of Galicia: The COPSIAD Study. PLoS One. 2013 Jun 18;8(6):e66451. Go to original source... Go to PubMed...
  35. Salo R, Flower K, Kielstein A, et al. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Res. 2011;186(2-3):356-361. Go to original source... Go to PubMed...
  36. Akindipe T, Wilson D, Stein DJ. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metab. Brain. Dis. 2014; 29(2): 351-357. Go to original source... Go to PubMed...
  37. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001 Jul 15;50(2):71-83. Go to original source... Go to PubMed...
  38. Green AI, Drake RE, Brunette MF, et al. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007;164(3):402-8. Go to original source... Go to PubMed...
  39. Gicas KM, Parmar PK, Fabiano GF, Mashhadi F. Substance-induced psychosis and cognitive functioning: A systematic review. Psychiatry Res. 2022;308:114361. Go to original source... Go to PubMed...
  40. Caton CL, Hasin DS, Shrout PE, et al. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. Br J Psychiatry. 2007;190:105-11. Go to original source... Go to PubMed...
  41. Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, et al. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug Alcohol Rev. 2010;29(4):456-61. Go to original source... Go to PubMed...
  42. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. Am J Psychiatry. 2018 Apr 1;175(4):343-350. doi: 10.1176/appi.ajp.2017.17020223. Epub 2017 Nov 28. Erratum in: Am J Psychiatry. 2019 Apr 1;176(4):324. Go to original source... Go to PubMed...
  43. Murrie B, Lappin J, Large M, Sara G. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2020 Apr 10;46(3):505-516. Go to original source... Go to PubMed...
  44. Niemi-Pynttäri JA, Sund R, Putkonen H, et al. Substance-induced psychoses converting into schizophrenia: a register-based study of 18,478 Finnish inpatient cases. J Clin Psychiatry. 2013 Jan;74(1):e94-9. Go to original source... Go to PubMed...
  45. Arendt M, Rosenberg R, Foldager L, et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187:510-5. Go to original source... Go to PubMed...
  46. Kendler KS, Ohlsson H, Sundquist J, et al. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample. Am J Psychiatry. 2019;176(9):711-719. Go to original source... Go to PubMed...
  47. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiat (Suppl.) 1997; 154: 1-63. Go to original source... Go to PubMed...
  48. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53. Go to original source... Go to PubMed...
  49. Pompili M, Amador FX, Girardi P, et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann Clin Psychiatry. 2007; 6: 10. Go to original source... Go to PubMed...
  50. Chai Y, Luo H, Wei Y, et al. Risk of self-harm or suicide associated with specific drug use disorders, 2004-2016: a population-based cohort study. Addiction. 2022;117(7):1940-1949. Go to original source... Go to PubMed...
  51. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014;28(12):1115-26. Go to original source... Go to PubMed...
  52. Masopust J, Kopeček M., Protopopová D. Stabilizační a udržovací léčba schizofrenie. Doporučené postup psychiatrické péče 2022. https://postupy-pece.psychiatrie.cz/specialni-psychiatrie/f2-schizofrenie/stabilizacni-udrzovaci-lecba-schizofrenie.
  53. Zarrabi H, Khalkhali M, Hamidi A, et al. Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients. BMC Psychiatry. 2016 Feb;16:44. Go to original source... Go to PubMed...
  54. Campbell EC, Caroff SN, Mann SC. Pharmacotherapy for co-occurring schizophrenia and substance use disorder. UpToDate, Waltham, MA, Wolters Klumer Health. 2024 Feb.
  55. Medhus S, Mordal J, Holm B, et al. A comparison of symptoms and drug use between patients with methamphetamine associated psychoses and patients diagnosed with schizophrenia in two acute psychiatric wards. Psychiatry Res. 2013 Mar 30;206(1):17-21. Go to original source... Go to PubMed...
  56. Srisurapanont M, Arunpongpaisal S, Wada K, et al. Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):959-64. Go to original source... Go to PubMed...
  57. Shelly J, Uhlmann A, Sinclair H, et al. First-Rank Symptoms in Methamphetamine Psychosis and Schizophrenia. Psychopathology. 2016;49(6):429-435. Go to original source... Go to PubMed...
  58. Wang LJ, Lin SK, Chen YC, et al. Differences in Clinical Features of Methamphetamine Users with Persistent Psychosis and Patients with Schizophrenia. Psychopathology. 2016;49(2):108-15. Go to original source... Go to PubMed...
  59. Sekiguchi Y, Okada T, Okumura Y. Treatment Response Distinguishes Persistent Type of Methamphetamine Psychosis From Schizophrenia Spectrum Disorder Among Inmates at Japanese Medical Prison. Front Psychiatry. 2021 Jul 19;12:629315. Go to original source... Go to PubMed...
  60. Hajebi A, Amini H, Kashani L, Sharifi V. Twelve-month course and outcome of methamphetamine-induced psychosis compared with first episode primary psychotic disorders. Early Interv Psychiatry. 2018 Oct;12(5):928-934. Go to original source... Go to PubMed...
  61. Jordaan GP, Emsley R. Alcohol-induced psychotic disorder: a review. Metab Brain Dis. 2014 Jun;29(2):231-43. Go to original source... Go to PubMed...
  62. Rentero D, Arias F, Sánchez-Romero S, et al. Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use. Adicciones. 2021 Mar 31;33(2):95-108. Go to original source... Go to PubMed...
  63. Rubio G, Marín-Lozano J, Ferre F, et al. Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis. Compr Psychiatry. 2012 Nov;53(8):1063-70. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.